Tiziana Life Sciences not to engage in capital raising activities for the immediate future
Tiziana Life Sciences (Nasdaq: TLSA) has announced its decision not to engage in capital raising activities in the immediate future. This announcement follows the company's recent discovery of new immune biomarkers in patients with non-active secondary progressive multiple sclerosis (na-SPMS) treated with nasal foralumab, their lead development candidate. Foralumab is a fully human, anti-CD3 monoclonal antibody being developed as an intranasal immunomodulation therapy. The company's management emphasized their commitment to delivering shareholder value and advancing their drug candidates through clinical trials and regulatory processes.
Tiziana Life Sciences (Nasdaq: TLSA) ha annunciato la sua decisione di non intraprendere attività di raccolta di capitali nel prossimo futuro. Questa dichiarazione segue la recente scoperta da parte della società di nuovi biomarcatori immunitari in pazienti con sclerosi multipla secondaria progressiva non attiva (na-SPMS) trattati con foralumab nasale, il loro candidato principale allo sviluppo. Il foralumab è un anticorpo monoclonale anti-CD3 completamente umano, sviluppato come terapia di immunomodulazione intranasale. La direzione della società ha sottolineato il proprio impegno a garantire valore per gli azionisti e a portare avanti i loro candidati farmaceutici attraverso studi clinici e processi normativi.
Tiziana Life Sciences (Nasdaq: TLSA) ha anunciado su decisión de no participar en actividades de recaudación de capital en un futuro inmediato. Este anuncio sigue al reciente descubrimiento por parte de la compañía de nuevos biomarcadores inmunitarios en pacientes con esclerosis múltiple secundaria progresiva no activa (na-SPMS) tratados con foralumab nasal, su principal candidato en desarrollo. El foralumab es un anticuerpo monoclonal anti-CD3 completamente humano que se está desarrollando como una terapia de inmunomodulación intranasal. La dirección de la empresa subrayó su compromiso de ofrecer valor a los accionistas y avanzar en sus candidatos a medicamentos a través de ensayos clínicos y procesos regulatorios.
티치아나 생명과학 (나스닥: TLSA)는 가까운 미래에 자본 조달 활동을 하지 않기로 결정했다고 발표했습니다. 이 발표는 회사가 비활성 이차 진행성 다발성 경화증 (na-SPMS) 환자에서 비강으로 포랄루맙 치료받은 새로운 면역 바이오마커를 최근 발견한 것에 따른 것입니다. 포랄루맙은 전적으로 인간으로 이루어진 항-CD3 단클론 항체로, 비강 내 면역 조절 요법으로 개발되고 있습니다. 회사의 경영진은 주주 가치를 제공하고 임상 시험 및 규제 과정을 통해 약물 후보를 진전시키겠다는 의지를 강조했습니다.
Tiziana Life Sciences (Nasdaq: TLSA) a annoncé sa décision de ne pas s'engager dans des activités de levée de fonds dans un avenir proche. Cette annonce fait suite à la récente découverte par la société de nouveaux biomarqueurs immunitaires chez des patients atteints de sclérose en plaques secondaire progressive non active (na-SPMS) traités avec du foralumab nasal, leur principal candidat au développement. Le foralumab est un anticorps monoclonal anti-CD3 entièrement humain en cours de développement en tant que thérapie d'immunomodulation intranasale. La direction de l'entreprise a souligné son engagement à offrir de la valeur aux actionnaires et à faire progresser ses candidats médicaments à travers des essais cliniques et des processus réglementaires.
Tiziana Life Sciences (Nasdaq: TLSA) hat beschlossen, in naher Zukunft keine Kapitalbeschaffungsaktivitäten durchzuführen. Diese Ankündigung folgt auf die kürzliche Entdeckung neuer immunologischer Biomarker bei Patienten mit nicht aktiver sekundärer progredienter Multipler Sklerose (na-SPMS), die mit nasalem Foralumab behandelt wurden, ihrem führenden Entwicklungs-Kandidaten. Foralumab ist ein vollständig humaner, anti-CD3 monoklonaler Antikörper, der als intranasale Immunmodulationstherapie entwickelt wird. Das Management des Unternehmens betonte sein Engagement für die Schaffung von Aktionärswert und die Weiterentwicklung ihrer Arzneimittelkandidaten durch klinische Studien und regulatorische Prozesse.
- Company has sufficient capital for immediate future operations
- No immediate share dilution risk for current shareholders
- None.
Insights
The announcement of Tiziana's decision to forgo immediate capital raising activities carries significant implications for investors and merits careful analysis. This strategic move, coming directly after their breakthrough announcement regarding new immune biomarkers in na-SPMS patients, appears deliberately timed to signal financial confidence to the market.
From a financial perspective, this decision suggests two critical insights: First, the company likely maintains a sufficient cash runway to support their immediate operational needs and ongoing clinical trials. Second, management may believe their recent scientific progress could lead to more favorable financing terms in the future, making current capital raising unnecessary or potentially dilutive at current valuations.
However, investors should note several key considerations:
- Biotechnology companies typically maintain high cash burn rates during clinical development phases
- The term "immediate future" remains undefined, leaving room for potential capital raising activities in the medium term
- This strategy could indicate management's expectation of near-term catalysts that could improve their financing options
The timing of this announcement, immediately following positive clinical developments, appears strategically calculated to maximize investor confidence and potentially support share price stability. However, prudent investors should closely monitor the company's cash position and burn rate in upcoming quarterly reports to better assess the sustainability of this strategy.
NEW YORK, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announces its intention not to engage in a capital raising activities for the immediate future.
Following on from its news yesterday of the discovery of new immune biomarkers in patients with non-active secondary progressive multiple sclerosis (na-SPMS) treated with nasal foralumab, the Company has decided not to engage in a capital raising activities for the immediate future.
Tiziana’s management team remains committed to delivering value to its shareholders and advancing its innovative drug candidates through clinical trials and regulatory processes.
About Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative nasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb currently in clinical development, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.
For more information about Tiziana Life Sciences and its innovative pipeline of therapies, please visit www.tizianalifesciences.com.
Forward-Looking Statements
Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry, its beliefs, and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled ‘Risk Factors’ in Tiziana’s Annual Report on Form 20-F for the year ended December 31, 2023, and other periodic reports filed with the Securities and Exchange Commission.The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.
For further inquiries:
Tiziana Life Sciences Ltd
Paul Spencer, Business Development, and Investor Relations
+44 (0) 207 495 2379
email: info@tizianalifesciences.com
FAQ
Why did Tiziana Life Sciences (TLSA) announce no capital raising activities?
What is the impact of TLSA's no capital raising announcement on shareholders?
What is Tiziana Life Sciences' (TLSA) main development candidate?
What recent discovery did TLSA announce before the no-capital-raising decision?
